Recombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]

Απλή σελίδα τεκμηρίου
dc.contributor.authorGeorgopoulos, D.en
dc.contributor.authorMatamis, D.en
dc.contributor.authorRoutsi, C.en
dc.contributor.authorMichalopoulos, A.en
dc.contributor.authorMaggina, N.en
dc.contributor.authorDimopoulos, G.en
dc.contributor.authorZakynthinos, E.en
dc.contributor.authorNakos, G.en
dc.contributor.authorThomopoulos, G.en
dc.contributor.authorMandragos, K.en
dc.contributor.authorManiatis, A.en
dc.date.accessioned2015-11-24T18:54:51Z
dc.date.available2015-11-24T18:54:51Z
dc.identifier.issn1466-609X-
dc.identifier.urihttps://olympias.lib.uoi.gr/jspui/handle/123456789/18760
dc.rightsDefault Licence-
dc.subjectAdulten
dc.subjectAgeden
dc.subjectAged, 80 and overen
dc.subjectBlood Transfusion/*utilizationen
dc.subjectDose-Response Relationship, Drugen
dc.subjectEpidemiologic Methodsen
dc.subjectErythrocytes/*drug effectsen
dc.subjectErythropoietin/*administration & dosageen
dc.subjectFemaleen
dc.subjectHemoglobins/*drug effectsen
dc.subjectHumansen
dc.subjectIron/therapeutic useen
dc.subjectMaleen
dc.subjectMiddle Ageden
dc.subjectRecombinant Proteinsen
dc.subjectTime Factorsen
dc.titleRecombinant human erythropoietin therapy in critically ill patients: a dose-response study [ISRCTN48523317]en
heal.abstractINTRODUCTION: The aim of this study was to assess the efficacy of two dosing schedules of recombinant human erythropoietin (rHuEPO) in increasing haematocrit (Hct) and haemoglobin (Hb) and reducing exposure to allogeneic red blood cell (RBC) transfusion in critically ill patients. METHOD: This was a prospective, randomized, multicentre trial. A total of 13 intensive care units participated, and a total of 148 patients who met eligibility criteria were enrolled. Patients were randomly assigned to receive intravenous iron saccharate alone (control group), intravenous iron saccharate and subcutaneous rHuEPO 40,000 units once per week (group A), or intravenous iron saccharate and subcutaneous rHuEPO 40,000 units three times per week (group B). rHuEPO was given for a minimum of 2 weeks or until discharge from the intensive care unit or death. The maximum duration of therapy was 3 weeks. RESULTS: The cumulative number of RBC units transfused, the average numbers of RBC units transfused per patient and per transfused patient, the average volume of RBCs transfused per day, and the percentage of transfused patients were significantly higher in the control group than in groups A and B. No significant difference was observed between group A and B. The mean increases in Hct and Hb from baseline to final measurement were significantly greater in group B than in the control group. The mean increase in Hct was significantly greater in group B than in group A. The mean increase in Hct in group A was significantly greater than that in control individuals, whereas the mean increase in Hb did not differ significantly between the control group and group A. CONCLUSION: Administration of rHuEPO to critically ill patients significantly reduced the need for RBC transfusion. The magnitude of the reduction did not differ between the two dosing schedules, although there was a dose response for Hct and Hb to rHuEPO in these patients.en
heal.accesscampus-
heal.fullTextAvailabilityTRUE-
heal.identifier.primary10.1186/cc3786-
heal.identifier.secondaryhttp://www.ncbi.nlm.nih.gov/pubmed/16277712-
heal.identifier.secondaryhttp://ccforum.com/content/pdf/cc3786.pdf-
heal.journalNameCrit Careen
heal.journalTypepeer-reviewed-
heal.languageen-
heal.publicationDate2005-
heal.recordProviderΠανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικήςel
heal.typejournalArticle-
heal.type.elΆρθρο Περιοδικούel
heal.type.enJournal articleen

Αρχεία

Πρωτότυπος φάκελος/πακέτο

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
Georgopoulos-2005-Recombinant human er.pdf
Μέγεθος:
184.45 KB
Μορφότυπο:
Adobe Portable Document Format
Κατεβάστε

Φάκελος/Πακέτο αδειών

Προβολή: 1 - 1 of 1
Μικρογραφία εικόνας
Ονομα:
license.txt
Μέγεθος:
1.74 KB
Μορφότυπο:
Item-specific license agreed upon to submission
Περιγραφή:
Κατεβάστε

Συλλογές

Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ